Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Revenue (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Revenue for 15 consecutive years, with $11800.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue fell 94.95% year-over-year to $11800.0, compared with a TTM value of $383400.0 through Sep 2025, up 1.7%, and an annual FY2024 reading of $401000.0, up 175.03% over the prior year.
  • Revenue was $11800.0 for Q3 2025 at BioRestorative Therapies, down from $303300.0 in the prior quarter.
  • Across five years, Revenue topped out at $303300.0 in Q2 2025 and bottomed at $3700.0 in Q4 2022.
  • Average Revenue over 5 years is $55405.3, with a median of $29000.0 recorded in 2022.
  • The sharpest move saw Revenue soared 660.91% in 2024, then crashed 94.95% in 2025.
  • Year by year, Revenue stood at $5000.0 in 2021, then fell by 26.0% to $3700.0 in 2022, then surged by 421.62% to $19300.0 in 2023, then skyrocketed by 124.35% to $43300.0 in 2024, then tumbled by 72.75% to $11800.0 in 2025.
  • Business Quant data shows Revenue for BRTX at $11800.0 in Q3 2025, $303300.0 in Q2 2025, and $25000.0 in Q1 2025.